Consider 505(b)(2) Pathway [Design Issues]

posted by bebac_fan – US, 2018-05-05 17:08 (1270 d 12:20 ago) – Posting: # 18756
Views: 2,428

I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.

In this case, comparative efficacy, rather than BE, will be considered pivotal.

Complete thread:

Activity
 Admin contact
21,758 posts in 4,550 threads, 1,544 registered users;
online 3 (0 registered, 3 guests [including 1 identified bots]).
Forum time: Wednesday 05:28 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5